A carregar...
Eculizumab and Recurrent C3 Glomerulonephritis
BACKGROUND AND OBJECTIVES: Hyperactivity of the alternative complement pathway is the principle defect in the C3 glomerulopathies (C3G). Eculizumab, a monoclonal antibody that binds to C5 to prevent formation of the membrane attack complex, has been shown to be beneficial in some patients with this...
Na minha lista:
| Publicado no: | Pediatr Nephrol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4428658/ https://ncbi.nlm.nih.gov/pubmed/23689905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00467-013-2503-y |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|